Obeticholic Acid and Edaravone Protect Against Cisplatin‐Induced Hepatotoxicity Through Modulation of Keap1/Nrf2/ARE, TNF‐α/NF‐κB, and AKT/GSK‐3β Pathways
Fares E. M. Ali, Adel G. Bakr, Abdel‐Gawad S. Shalkami, Ehab A. M. El‐Shoura, Lamiaa Khalaf Ahmed, Ali F. Abd‐Elsalam, Ahmed A. N. Ahmed, Emad H. M. Hassanein · 2026
Read Obeticholic Acid and Edaravone Protect Against Cisplatin‐Induced Hepatotoxicity Through Modulation of Keap1/Nrf2/ARE, TNF‐α/NF‐κB, and AKT/GSK‐3β Pathways by Fares E. M. Ali, Adel G. Bakr, Abdel‐Gawad S. Shalkami, Ehab A. M. El‐Shoura, Lamiaa Khalaf Ahmed, Ali F. Abd‐Elsalam, Ahmed A. N. Ahmed, Emad H. M. Hassanein (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13539285.txt.
Description
Fares Ali and co-authors tested two protective drugs in rats in 2026 against liver damage from a common chemotherapy agent. The chemo drug cures cancers but can inflame and kill liver tissue, limiting its use.
Rats got the chemo drug alone or with a bile acid drug, a radical scavenger drug, or both. Both add on drugs eased the damage: liver enzymes settled, tissue structure held, and the balance of stress chemistry improved. Inflammation signals fell and cell death signaling eased. The pair together did best, acting through defense, inflammation, and survival pathways in the liver cells. The authors suggest the combo could shield patients' livers during treatment, pending human tests.
Catalog record
| CREATOR | Fares E. M. Ali, Adel G. Bakr, Abdel‐Gawad S. Shalkami, Ehab A. M. El‐Shoura, Lamiaa Khalaf Ahmed, Ali F. Abd‐Elsalam, Ahmed A. N. Ahmed, Emad H. M. Hassanein |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |